CN112939981B - Nucleoside compound, pharmaceutically acceptable salt, composition and application thereof - Google Patents
Nucleoside compound, pharmaceutically acceptable salt, composition and application thereof Download PDFInfo
- Publication number
- CN112939981B CN112939981B CN202110066452.XA CN202110066452A CN112939981B CN 112939981 B CN112939981 B CN 112939981B CN 202110066452 A CN202110066452 A CN 202110066452A CN 112939981 B CN112939981 B CN 112939981B
- Authority
- CN
- China
- Prior art keywords
- compound
- virus
- composition
- cell
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 Nucleoside compound Chemical class 0.000 title claims abstract description 44
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 239000002777 nucleoside Substances 0.000 title claims abstract description 34
- 150000003839 salts Chemical class 0.000 title abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 23
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims description 76
- 241000700605 Viruses Species 0.000 claims description 36
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 7
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 2
- 230000019491 signal transduction Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 241000714201 Feline calicivirus Species 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 16
- 241000282324 Felis Species 0.000 abstract description 13
- 208000003265 stomatitis Diseases 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 73
- 238000012360 testing method Methods 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 230000003833 cell viability Effects 0.000 description 11
- 239000007788 liquid Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000000120 cytopathologic effect Effects 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 241000711573 Coronaviridae Species 0.000 description 8
- 244000309467 Human Coronavirus Species 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000002458 infectious effect Effects 0.000 description 8
- 230000009385 viral infection Effects 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 7
- 230000000840 anti-viral effect Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 208000001528 Coronaviridae Infections Diseases 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 241001678559 COVID-19 virus Species 0.000 description 5
- 241000282326 Felis catus Species 0.000 description 5
- 230000003187 abdominal effect Effects 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 230000008014 freezing Effects 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 229910052805 deuterium Inorganic materials 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 208000005098 feline infectious peritonitis Diseases 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- APRZHQXAAWPYHS-UHFFFAOYSA-N 4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=C(OCC(O)=O)C=CC=2)=NN1C1=CC=C(S([O-])(=O)=O)C=C1 APRZHQXAAWPYHS-UHFFFAOYSA-N 0.000 description 2
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000725579 Feline coronavirus Species 0.000 description 2
- 241000711475 Feline infectious peritonitis virus Species 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 238000002737 cell proliferation kit Methods 0.000 description 2
- 238000012200 cell viability kit Methods 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 150000002431 hydrogen Chemical group 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- 230000035502 ADME Effects 0.000 description 1
- 208000006339 Caliciviridae Infections Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000867607 Chlorocebus sabaeus Species 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 231100000645 Reed–Muench method Toxicity 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Chemical group 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Chemical group 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a nucleoside compound, pharmaceutically acceptable salts, a composition and application thereof, wherein the nucleoside compound has a structure shown in a formula (I):
Description
Technical Field
The invention relates to the technical field of medicinal chemistry, in particular to a nucleoside compound, a composition and application thereof.
Background
Feline calicivirus is a single-stranded RNA virus without an envelope and with a spherical capsid, is highly contagious, can cause moderate and self-limited acute oral problems and upper respiratory diseases, and is one of the most common pathogenies of feline infectious upper respiratory diseases. At present, no targeted medicine is available for the cat stomatitis problem caused by the feline calicivirus, hormones or antibiotics are generally adopted for the supportive therapy, the cat stomatitis is easy to relapse, and the cat stomatitis is treated by a full-mouth tooth extraction operation in severe cases, so that great pain is brought to the cat. Therefore, a series of effective anti-calicivirus compounds are urgently needed.
Disclosure of Invention
Based on the above, there is a need for a nucleoside compound, a composition and a use thereof. The nucleoside compound has a better effect of resisting feline calicivirus, so the nucleoside compound has the potential of preparing medicaments for treating or preventing related diseases caused by the feline calicivirus.
A nucleoside compound having the structure represented by formula (I):
wherein:
R 1 is-H, halogen, -CN, -C 1-6 Alkane, C 2-6 Olefins or C 2-6 An alkyne;
R 3 is-H or-CN;
R 4 is-H or-CN.
In one embodiment, R 1 is-H, -F, -Br, -I or-CN; and/or
R 4 is-H or-CN.
In one embodiment, R 1 、R 3 And R 4 At least one of which is-CN.
In one embodiment, the nucleoside compound is selected from any one of the following compounds:
a composition comprising at least one nucleoside compound as described above.
In one embodiment, the composition further comprises a therapeutic agent.
In one embodiment, the therapeutic agent is one or more of a corticosteroid, a protease inhibitor, and an anti-inflammatory signal transduction modulator.
In one embodiment, the therapeutic agent is a compound of formula (II):
the use of the above nucleoside compound or the above composition for the preparation of a medicament for the treatment or prevention of feline calicivirus infection, feline infectious abdoviral infection, or disease caused by coronavirus infection.
In one embodiment, the disease caused by feline calicivirus is feline stomatitis.
In one embodiment, the disease caused by feline infectious abdominal virus infection is feline infectious peritonitis.
In one embodiment, the coronavirus is human coronavirus (HCoV)229E or a novel coronavirus SARS-CoV-2.
Advantageous effects
The nucleoside compound has better effect of resisting feline calicivirus, so the nucleoside compound has the potential of preparing medicaments for treating or preventing diseases (such as feline stomatitis) caused by the feline calicivirus.
Detailed Description
In order that the invention may be more fully understood, a more particular description of the invention will now be rendered by reference to specific embodiments thereof that are illustrated in the appended drawings. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items.
Interpretation of terms
"alkyl" refers to a saturated aliphatic hydrocarbon group, including straight and branched chain groups. C 1-6 Alkyl refers to an alkyl group containing 1 to 6 carbon atoms. Non-limiting examples include: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1-dimethylpropyl, 1, 2-dimethylpropyl, 2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1, 2-trimethylpropyl, 1-dimethylbutyl, 1, 2-dimethylbutyl, 2-dimethylbutyl, 1, 3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2, 3-dimethylbutyl. C 1-4 Alkyl refers to an alkyl group containing 1 to 4 carbon atoms. In one embodiment, C 1-4 The alkyl group is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl or sec-butyl. Alkyl groups may be substituted or unsubstituted, and when substituted, the substituent may be substituted at any available point of attachment.
"alkenyl" refers to hydrocarbons containing a normal, secondary, tertiary, or ring carbon atom having at least one site of unsaturation, i.e., a carbon-carbon sp2 double bond. Phrases containing the term, e.g., "C2 -6 The alkenyl group "means an alkenyl group having 2 to 6 carbon atoms. Suitable examples include, but are not limited to: vinyl (-CH ═ CH2), allyl (-CH2CH ═ CH2), cyclopentenyl (-C5H7) and 5-hexenyl (-CH2CH ═ CH 2).
"alkynyl" refers to a hydrocarbon containing a normal, secondary, tertiary, or ring carbon atom having at least one site of unsaturation, i.e., a carbon-carbon sp triple bond. Phrases containing this term, such as "C2- 6 The alkynyl group means an alkynyl group having 2 to 6 carbon atoms. Suitable examples include, but are not limited to: ethynyl (-C.ident.CH) and propargyl (-CH 2C.ident.CH).
In the description of the present invention, "a plurality" means two or more unless specifically defined otherwise.
The compounds of the present invention may exist in unsolvated forms as well as solvated forms containing pharmaceutically acceptable solvents such as water, ethanol, and the like, i.e., both solvated and unsolvated forms.
In the present invention, a certain substitutable site may be substituted with one or more substituents, and when a plurality of substituents are present at the substitutable site, the plurality of substituents may be the same as or different from each other.
In the present invention, a pharmaceutical may comprise, in addition to one or more of the compounds or compositions described herein, a mixture of a physiologically/pharmaceutically acceptable salt or prodrug and other chemical components, as well as other components. Such as physiologically/pharmaceutically acceptable carriers and excipients. Among the excipients, may be one or more buffers, stabilizers, anti-adherents, surfactants, wetting agents, lubricants, emulsifiers, binders, suspending agents, disintegrants, fillers, adsorbents, preservatives (enteric or sustained release), antioxidants, opacifying agents, glidants, processing aids, colorants, sweeteners, fragrances, flavoring agents, and other known additives.
In addition, the pharmaceutical preparation containing the compound may be tablets, capsules, oral liquids, pills, granules, powders, ointments, patches, suppositories, buccal tablets, eye drops, eye ointments, ear drops, sprays, aerosols, inhalants, injections, and the like.
The term "therapeutically effective amount" means an amount of an effective compound or pharmaceutical agent that is the minimum amount necessary to ameliorate, cure or treat one or more symptoms of a disease or condition.
In addition, the compounds and compositions of the present invention may be administered alone or in combination with other agents. For combination therapy with more than one active agent, when the active agents are in separate dosage formulations, the active agents may be administered separately or in combination. In addition, administration of one agent may be performed before, simultaneously with, or after administration of another agent. When administered in combination with other agents, the "effective amount" of the second agent will depend on the type of drug used.
The present invention encompasses all crystalline and amorphous forms of the compounds. In some embodiments, the compounds also represent unlabeled as well as isotopically labeled forms of the compounds. Isotopically-labeled compounds have the structure given herein in which one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, such as, but not limited to, 2H (deuterium, D), 3H (tritium), 11C, 13C, 14C, 15N, 18F, 31P, 32P, 35S, 36Cl, and 125I. The invention also includes compounds in which 1 to n of the hydrogens attached to the carbon atoms are replaced with deuterium, where n is the number of hydrogens in the molecule. The compounds exhibit increased metabolic resistance and, therefore, can be used to increase the half-life of the compounds when administered to a mammal. Deuterium labeled or substituted compounds of the present invention may have improved DMPK (drug metabolism and pharmacokinetics) properties with respect to distribution, metabolism and excretion (ADME). Substitution with heavier isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life, reduced dosage requirements and/or improved therapeutic index. In the compounds of the present invention, any atom not specifically designated as a specific isotope is intended to represent any stable isotope of that atom. Unless otherwise stated, when a position is specifically designated as H or hydrogen, that position is understood to have hydrogen in its natural abundance isotopic composition.
Route of administration
One or more compounds of the invention are administered by any route appropriate to the organism being treated (e.g., cat). Suitable routes include oral, rectal, nasal, pulmonary, topical (including buccal and sublingual), and parenteral (including subcutaneous, intramuscular), and the like.
The compounds or pharmaceutical compositions of the present invention may also be included in a kit.
Detailed explanation
One embodiment of the present invention provides a nucleoside compound having a structure represented by formula (I):
wherein:
R 1 is-H, halogen, -CN, -C 1-6 Alkane, C 2-6 Olefins or C 2-6 An alkyne;
R 3 is-H or-CN;
R 4 is-H or-CN.
In one embodiment, in the structure of formula (I), R 1 is-H, halogen, -CN, methyl, ethyl, propyl, isopropyl, ethenyl, propenyl, ethynyl or propynyl.
In one embodiment, in the structure of formula (I), R 1 is-H, -F, -Br, -I or-CN.
In one embodiment, in the structure of formula (I), R 4 is-H or-CN.
In one embodiment, in the structure of formula (I), R 3 is-H or-CN.
In one embodiment, in the structure of formula (I), R 1 、R 3 And R 4 At least one of which is-CN.
In one embodiment, the nucleoside compound is selected from any one of the following compounds:
an embodiment of the present invention also provides a composition comprising the above nucleoside compound.
In one embodiment, the composition comprises two or more of the nucleoside compounds.
In one embodiment, the composition comprises at least one compound of the following structure:
in one embodiment, the composition comprises at least one nucleoside compound. Further, the above composition further comprises a therapeutic agent.
In one embodiment, the therapeutic agent is a compound of formula (II):
the compound with the structure shown in the formula (I) and the compound shown in the formula (II) are combined to form a composition, and the experimental result shows that the components have obvious synergistic effect and have obvious inhibition effect in experiments of resisting feline calicivirus, feline infectious abdominal virus infection and coronavirus infection. The compositions of the present invention are shown to have potential for the treatment of diseases caused by feline calicivirus, coronavirus infection.
In one embodiment, the composition is composed of a nucleoside compound represented by formula (I) and a compound represented by formula (II).
An embodiment of the present invention provides use of the above nucleoside compound or the above composition for the preparation of a medicament for treating or preventing an antiviral.
One embodiment of the present invention provides the use of the above nucleoside compound or the above composition for the preparation of a medicament for treating or preventing diseases caused by feline calicivirus.
In one embodiment, the disease caused by feline calicivirus is feline stomatitis.
An embodiment of the present invention provides a method for treating or preventing diseases caused by feline calicivirus, comprising the step of administering an effective amount of the above nucleoside compound or the above composition to a subject to be treated.
An embodiment of the present invention provides a use of the above nucleoside compound or the above composition for the preparation of a medicament for treating or preventing a disease caused by feline infectious abdominal virus infection.
In one embodiment, the disease caused by feline infectious peritonitis is feline infectious peritonitis.
An embodiment of the present invention provides a method for treating or preventing a disease caused by feline-transmitted abdominal virus infection, comprising the step of administering an effective amount of the above nucleoside compound or the above composition to a subject to be treated.
An embodiment of the present invention provides a use of the above nucleoside compound or the above composition for the preparation of a medicament for treating or preventing a disease caused by coronavirus infection.
In one embodiment, the coronavirus is human coronavirus (HCoV) 229E.
In one embodiment, the coronavirus is a feline coronavirus.
In one embodiment, the coronavirus is a novel coronavirus SARS-CoV-2.
An embodiment of the present invention provides a method for treating or preventing a disease caused by coronavirus infection, comprising the step of administering an effective amount of the above nucleoside compound or the above composition to a subject to be treated.
Further, the subject to be treated is a human or a veterinary; further, the subject to be treated is a human or a cat.
An embodiment of the present invention provides a medicament comprising 1) the above nucleoside compound or the above composition; 2) pharmaceutically acceptable adjuvants.
An embodiment of the present invention provides a feed comprising the above nucleoside compound or the above composition.
The present invention will be described below with reference to specific examples.
The compounds in the following examples are each:
example 1
To a mixture of compound a (0.20g) and DMF (2mL) was added N-bromosuccinimide (NBS) (122mg), and the mixture was stirred at 10-20 ℃ for 1 hour. LCMS monitoring indicated the formation of target Ms and the reaction was prepared for purification. Compound a-1 (0.20g, 78.5% yield, 99.7% purity) was obtained as a white solid. 1 HNMR:(400MHz, DMSO-d6)：δ7.98(s,H),7.06(s,1H),6.25(s,1H),5.20(s,1H), 4.93(m,1H),4.53(dd,1H),4.05(m,1H),3.93(m,1H),3.64-3.67(m, 1H),3.48-3.51(m,1H).
To a mixture of Compound a-1(0.50g) and DMF (2mL) was added Zn (CN) 2 (0.67g,5.71mmol, 362. mu.L, 5.99eq), CuI (18.2mg, 95.3. mu. mol,0.10 eq) and Pd (PPh) 3 ) 4 (441mg, 381. mu. mol,0.40eq), under nitrogen, and the reaction was stirred at 140 ℃ for 2 hours. LCMS showed generation of target Ms. The reaction was filtered, and 10mL of water was added to the filtrate, followed by extraction with dichloromethane (20mL × 2). After liquid separation, organic phases are combined and concentrated to be dried to obtain a crude product of the compound a-2, and the crude product is sent to preparation and purification to obtain 0.18g of the compound a-2 with the HPLC purity of 97.9%. 1 HNMR:(400MHz, DMSO-d6)：δ8.21(s,1H),7.48(s,1H),6.29(d,1H),5.20(s,1H), 4.93(m,1H),4.53(dd,1H),4.05(m,1H),3.93(m,1H),3.65(m,1H), 3.53(m,1H),2.61(m,2H).
To a mixture of compound a-2(0.15g) and pyridine (10mL) was added N, N-dimethylformamide dimethyl acetal (0.12g), and the reaction mixture was stirred at 10-20 ℃ for 2.5 hours. The reaction was monitored by thin layer silica gel chromatography and a new spot was observed (EA: MeOH 9:1, R) f 0.4), the reaction solution was concentrated under reduced pressure and purified to obtain compound 1(0.11g, 97.2% purity) as a white solid. 1 HNMR:(400MHz,D 2 O)：δ 8.82(s,1H),8.02(s,1H),7.21(d,1H),4.91(d,1H),4.26-4.29(m, 1H),4.24-4.27(m,1H),3.87-3.89(m,1H),3.75-3.76(m,1H), 3.25-3.27(m,6H).
To a mixture of compound a (2.00g) and pyridine (56mL) was added N, N-dimethylformamide dimethyl acetal (1.23g), and the reaction mixture was stirred at 10-20 ℃ for 1.5 hours. Monitoring the reaction by thin-layer silica gel chromatography: shows a new point formation (EA: MeOH ═ 10:1, R) f 0.30). The reaction solution was concentrated under reduced pressure and purification was performed to obtain compound 2(2.11g,5.73mmol, 83.4% yield, 94.0% write) as a white solid. 1 HNMR: (400MHz,D 2 O)：δ8.79(s,1H),8.00(s,1H),7.03-7.04(d,1H), 6.92-6.94(d,1H),4.89-4.90(d,1H),4.28-4.30(m,1H),4.22-4.25(m, 1H),3.85-3.88(m,1H),3.73-3.75(m,1H),3.24-3.26(m,6H).
To a mixture of compound b (2.00g) and pyridine (60mL) was added N, N-dimethylformamide dimethyl acetal (1.25g), and the reaction mixture was stirred at 10-20 ℃ for 2.5 hours. Monitoring the reaction by thin-layer silica gel chromatography: shows a new point of formation (EA: MeOH ═ 10:1, R) f 0.42). The reaction solution was concentrated under reduced pressure and purification was performed to obtain compound 3(1.85g, 96.0% write) as a white solid. 1 H NMR(400MHz,CD 3 OD)δ8.65(s,1H),8.06(d,1H),6.77(d,1H),6.66(d,1H),5.49(d,1H), 4.46(t,1H),4.36(d,1H),3.85(d,1H),3.80(d,1H)，3.26-3.28(m, 6H).
Activity assay
1. Anti-feline calicivirus (FCV-Kaos) activity assay:
1.1 recovery of F81 cells (Cat kidney cells, purchased from ATCC):
1) opening a constant-temperature water bath kettle in advance, and setting the temperature to be 38 ℃;
2) taking out the cell freezing tube from the liquid nitrogen, putting the cell freezing tube into a water bath kettle for 2-3 min, and completely melting the cell liquid;
3) centrifuging the cell freezing tube for 1000r/min and 10 min;
4) discarding the upper layer liquid of the cell freezing tube in the biological safety cabinet, and taking care not to suck the cells;
5) adding 1mL of 10% DMEM medium along the wall of the cryopreservation tube, slightly adding the DMEM medium, and removing the liquid after cleaning, wherein the cells are not blown up;
6) adding 1mL of 10% DMEM medium into the freezing tube, and gently mixing uniformly;
7) adding the liquid into a T25 cell bottle, supplementing 5-6 mL of 10% DMEM medium, uniformly mixing, placing at 37 ℃ with 5% CO 2 Culturing in a constant temperature incubator, and observing the cell state every day.
1.2, subculture of F81 cells:
1) DMEM medium containing 8% newborn calf serum at 37 deg.C and 5% CO 2 Culturing F81 cells in a constant temperature incubator;
2) when the cells grow to a monolayer, pouring out the original culture solution in the cell bottle, sucking 2-3 mL of serum-free DMEM by using a Pasteur tube, adding the serum-free DMEM into the cell bottle, washing for three times, and pouring out the culture solution;
3) adding 2-3 mL of 0.05% pancreatin for digestion;
4) standing at 37 deg.C for 5% CO 2 Keeping constant temperature incubator for 1min until digestion is completed;
5) adding a proper volume of 8% DMEM medium into the culture bottle, and gently and uniformly blowing;
6) averagely dividing the liquid in the cell bottle into two new cell culture bottles, and supplementing each liquid to 5-6 mL;
7) the cell flask was placed at 37 ℃ and 5% CO 2 Culturing in a constant temperature incubator, and observing the cell state at intervals.
1.3 titration of viral infectivity (TCID) 50 Measurement of (2)
Feline FCV-Kaos virus (commercially available from ATCC american type culture collection) was serially diluted 10-fold in different concentrations with maintenance medium, and 3 wells were vertically repeated, sequentially inoculated into 96-well plates of host cells grown in monolayers, and cell controls were set. 37 ℃ and 5% CO 2 Culturing in virus incubator, observing day by day under inverted microscope, continuously observing for 96 hr, adding 1% neutral red 50 μ L, staining at 37 deg.C for 1 hr, discarding staining solution, washing excessive dye with washing solution, adding 100 μ L decolorizing solution, decolorizing at room temperature for 10min, and measuring OD value with enzyme reader at 540nm wavelength. Calculating the half infection concentration (TCID) of the virus liquid according to Reed-Muench formula 50 ):
Cell viability ═ (OD value-blank OD value)/(normal cell OD value-blank OD value for each group);
(ii) the rate of cell morbidity is 1-cell survival;
cell distance ═ (above 50% lesion rate-50%)/(-above 50% lesion rate-below 50% lesion rate);
TCID 50 anti lg (greater than 50% CPE percent virus dilution + beta);
TCID of FCV-Kaos Virus in F81 cells 50
The results are shown in Table 2:
TABLE 196 hours Virus TCID 50 Measurement of
1.4 antiviral test method of Compound
The cell maintenance solution for compound test sample is serially diluted by two times of the original concentration for 10 dilutionsSetting 3 multiple wells, adding 50 μ L each well into 96 wells transversely inoculated into F81 cat kidney cells grown into monolayer, adding 100 times of TCID into each well 50 The feline calicivirus FCV-Kaos 50 mu L is provided with a virus control group, a cell control group and a drug toxicity group, and 3 multiple wells. 37 ℃ and 5% CO 2 Culturing in incubator, observing cytopathic effect day by day, staining with 1% neutral red when virus contrast has more than 90% pathological changes, and measuring OD value with microplate reader at 540nm wavelength. The half effective concentration of the drug (EC50) was calculated using the Reed-Muench method:
EC50 ═ Antilog (value-distance of dilution of virus above 50% percent CPE) ] × C
(Note: C is the final concentration of the drug in the first well)
2. Detection of anti-feline-transmitted-abdominal-virus activity
2.1, a measuring method:
protection assay for feline infectious peritonitis virus cells feline kidney (CRFK) cells and FIPV-79-1146 (feline infectious abdominovirus) were used. Colloquially, the virus and cells are mixed and incubated for 7 days in the presence of the test compound. The virus was pre-titrated to cause control wells to undergo 85% to 95% apoptosis due to virus replication. Since the test compound inhibits viral replication, an antiviral effect is observed in the presence of the test compound. Each assay plate contained cell control wells (cells only), virus control wells (cells and virus), compound toxicity control wells (cells and compound only), compound colorimetric control wells (compound only), and experimental wells (compound, cells and virus). Determination of EC of cells by MTS (MTS (3- (4, 5-dimethylthiazol-2-yl) -5- (3-carboxymethoxyphenyl) -2- (4-sulfophenyl) -2H-tetrazolium) cell proliferation kit 50 (concentration of 50% cell survival) and cytotoxic CC 50 (concentration that resulted in 50% cell death).
2.2 cell preparation
Cat kidney (CRFK) cells (commercially available from the American Type Culture Collection (ATCC)) were grown in DMEM medium (2.0mM L-glutamine, 100 units/ml penicillin, and 100. mu.g/ml streptomycin) supplemented with 10% Fetal Bovine Serum (FBS). Using standard cell cultureThe method comprises the following steps of 1: the cells were subcultured twice a week at a split ratio of 10. Total cell number and percent viability were determined using a hemocytometer and trypan blue exclusion. For cells to be used in the assay, cell viability must be greater than 95%. 1X10 the day before the measurement 4 Concentration of individual cells/well cells were seeded in 96-well tissue culture plates.
2.3 preparation of viruses
The virus used for the assay was feline infectious abdominal virus FIPV-79-1146 (commercially available from the American Type Culture Collection (ATCC)) grown in CRFK cells, producing the virus and serving as a stock virus pool. For each assay, a pre-titrated aliquot of the virus was removed from-70 ℃ conditions and thawed to room temperature in a biosafety cabinet. The virus was then suspended and diluted into tissue culture medium such that the amount of virus added to each well was an amount determined to produce between 85% and 95% cell kill 4-5 days after infection.
2.4, cell staining
After 5 days of infection, cell viability was determined and compound toxicity quantified using MTS cell proliferation kit staining. Cell viability and cytotoxicity of the compounds were determined by quantifying the soluble formazan product produced by MTS metabolism by the mitochondrial enzyme that metabolises active cells. 20-25. mu.L of MTS reagent was added to each well, followed by 5% CO at 37 ℃ 2 Microtiter plates were incubated for 4-6 hours under conditions and cell viability was then determined. The plates were read spectrophotometrically at 490/650nm using a SpectraMax Plus plate reader.
3. Detection of anti-SARS-CoV-2 activity of novel coronavirus
Cytopathic effect (CPE) experiment, which detects the activity of the compound against human novel coronavirus SARS-CoV-2 in vitro and simultaneously detects the toxicity of the compound to green monkey kidney cell Vero-E6.
3.1 preparation of Compounds
Test compounds were formulated as 20mM stock solutions using DMSO solutions, and compounds were tested at 8 concentrations, diluted in 3-fold gradients, in duplicate wells.
3.2 Experimental protocol
Vero-E6 cells with good growth state are taken intoThe lines were subjected to digestion and passaged, using cell growth media to adjust cell density to a density of 10,000 cells per well, into 96-well test plates and incubated overnight in a 5% CO2, 37 ℃ incubator. The following day, compound diluted in multiples (8 concentration points, duplicate wells) was added, followed by virus at 200TCID per well 50 Cells were added. Cell controls (cells, no compound treatment or viral infection), virus controls (cells infected with virus, no compound treatment) and broth controls (broth only) were set. The final concentration of DMSO in the culture medium was 0.5%. The cells were cultured in a 5% CO2 incubator at 35 ℃ for 3 days. Cell viability was measured using the cell viability assay kit CellTiter Glo (Promega). The cytotoxicity test and the antiviral test are the same, but no virus infection exists. The antiviral activity and cytotoxicity of the compounds were represented by the inhibition rate (%) of the compound against the virus-induced cytopathic effect and the survival rate (%) of MRC5 cells at different concentrations, respectively. The calculation formula is as follows:
inhibition (%) ═ test well readings-mean of virus controls)/(mean of cell controls-mean of virus controls) × 100
Cell viability (%) — x 100 (test well reading-broth control average)/(cell control average-broth control average)
Non-linear fit analysis of inhibition and cell viability rates of compounds using GraphPad Prism (version 5) was performed to calculate half effective concentration (EC50) and half cytotoxic concentration (CC50) values for compounds.
4. Detection of anti-human coronavirus (HCoV)229E Activity
Cytopathic effect (CPE) assay, compounds were tested for in vitro anti-human coronavirus (HCoV)229E activity, and compounds were tested for toxicity to MRC5 cells.
4.1 preparation of Compounds
Test compounds were prepared as 20mM stock solutions using DMSO solutions, control compound Remdesivir, compound to be tested at 8 concentrations, 3-fold gradient dilutions, double wells.
4.2 cells and viruses
MRC5 cells and HCoV229E strain were purchased from ATCC. Cells were cultured in EMEM (Sigma) medium supplemented with 10% fetal bovine serum (Hyclone), 1% double antibody (Hyclone), 1% L-glutamine (Gibco) and 1% non-essential amino acids (Gibco). EMEM (Sigma) culture medium supplemented with 5% fetal bovine serum (Hyclone), 1% double antibody (Hyclone), 1% L-glutamine (Gibco) and 1% non-essential amino acid (Gibco) was used as experimental culture medium.
4.3 protocol
MRC5 cells were seeded at a density of 20,000 cells per well into 96 well test plates and cultured overnight in a 5% CO2, 37 ℃ incubator. The next day, compound diluted in multiple proportions (8 concentration points, duplicate wells) was added, followed by virus addition to cells at 200TCID50 per well. Cell controls (cells, no compound treatment or viral infection), virus controls (cells infected with virus, no compound treatment) and broth controls (broth only) were set. The final concentration of DMSO in the culture medium was 0.5%. The cells were cultured in a 5% CO2 incubator at 35 ℃ for 3 days. Cell viability was measured using the cell viability assay kit CellTiter Glo (Promega). The cytotoxicity test and the antiviral test have the same conditions, but no virus infection. The antiviral activity and cytotoxicity of the compounds were represented by the inhibition rate (%) of the compound against the virus-induced cytopathic effect and the survival rate (%) of MRC5 cells at different concentrations, respectively. The calculation formula is as follows:
inhibition (%) ═ test well readings-mean of virus controls)/(mean of cell controls-mean of virus controls) × 100
Cell viability (%) — x 100 (test well reading-broth control average)/(cell control average-broth control average)
Inhibition and cell viability of the compounds were analyzed by nonlinear fit using GraphPad Prism (version 5) and the median Effective Concentration (EC) of the compound was calculated 50 ) And half the Cytotoxic Concentration (CC) 50 ) The value is obtained.
Test article comparison compound:
TABLE 2
(a: less than 100nM, b: 100nM to 1000nM, c: 1000nM to 10. mu.M, d: more than 10. mu.M, FCV represents the result of detection of anti-feline calicivirus activity, FIPV represents the result of detection of anti-feline-transmissible-abdoviral activity, SARS-CoV-2 represents the result of detection of anti-novel coronavirus SARS-CoV-2 activity, HCoV229E represents the result of detection of anti-human coronavirus (HCoV)229E activity.)
As can be seen from the table above, the compound provided by the invention has stronger inhibitory action on feline calicivirus, feline infectious abdovirus, human coronavirus and feline coronavirus infection, and has the potential of preparing anti-virus medicaments.
The technical features of the embodiments described above may be arbitrarily combined, and for the sake of brevity, all possible combinations of the technical features in the embodiments described above are not described, but should be considered as being within the scope of the present specification as long as there is no contradiction between the combinations of the technical features.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
Claims (6)
1. A nucleoside compound characterized by being the following compound:
2. a composition comprising a nucleoside compound according to claim 1.
3. The composition of claim 2, wherein the composition further comprises a therapeutic agent.
4. The composition of claim 3, wherein the therapeutic agent is one or more of a corticosteroid, a protease inhibitor, and an anti-inflammatory signal transduction modulator.
5. The composition of claim 4, wherein the therapeutic agent is a compound of formula (II):
6. use of a nucleoside compound according to claim 1 or a composition according to any one of claims 2 to 5 in the manufacture of a medicament for the treatment or prophylaxis of a disease caused by infection with HCoV229E virus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110066452.XA CN112939981B (en) | 2021-01-19 | 2021-01-19 | Nucleoside compound, pharmaceutically acceptable salt, composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110066452.XA CN112939981B (en) | 2021-01-19 | 2021-01-19 | Nucleoside compound, pharmaceutically acceptable salt, composition and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112939981A CN112939981A (en) | 2021-06-11 |
| CN112939981B true CN112939981B (en) | 2022-08-26 |
Family
ID=76236090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110066452.XA Active CN112939981B (en) | 2021-01-19 | 2021-01-19 | Nucleoside compound, pharmaceutically acceptable salt, composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112939981B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11541071B1 (en) | 2021-12-16 | 2023-01-03 | Ascletis BioScience Co., Ltd | Nucleoside derivatives and methods of use thereof |
| CN114516875B (en) * | 2022-01-26 | 2023-07-21 | 苏州旺山旺水生物医药有限公司 | A kind of preparation method of nucleoside analogue VV116 |
| CN116354967A (en) * | 2023-01-18 | 2023-06-30 | 嘉兴金派特生物科技有限公司 | Crystal form of nucleoside compound and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107427529A (en) * | 2014-12-26 | 2017-12-01 | 埃莫里大学 | N4 OH cytidines and derivative and relative anti-viral uses |
| CN110613726A (en) * | 2019-09-25 | 2019-12-27 | 嘉兴金派特生物科技有限公司 | Application of nucleoside compound, medicine and preparation method thereof |
| CN111135184A (en) * | 2020-03-05 | 2020-05-12 | 华中农业大学 | Application of GS-441524 in the preparation of novel coronavirus SARS-CoV-2 inhibitor |
| CN111961057A (en) * | 2020-05-26 | 2020-11-20 | 李小冬 | Alpha-configuration nucleoside and application thereof in treating feline coronavirus infection |
-
2021
- 2021-01-19 CN CN202110066452.XA patent/CN112939981B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107427529A (en) * | 2014-12-26 | 2017-12-01 | 埃莫里大学 | N4 OH cytidines and derivative and relative anti-viral uses |
| CN110613726A (en) * | 2019-09-25 | 2019-12-27 | 嘉兴金派特生物科技有限公司 | Application of nucleoside compound, medicine and preparation method thereof |
| CN111135184A (en) * | 2020-03-05 | 2020-05-12 | 华中农业大学 | Application of GS-441524 in the preparation of novel coronavirus SARS-CoV-2 inhibitor |
| CN111961057A (en) * | 2020-05-26 | 2020-11-20 | 李小冬 | Alpha-configuration nucleoside and application thereof in treating feline coronavirus infection |
Non-Patent Citations (2)
| Title |
|---|
| Structural basis for repurpose and design of nucleoside drugs for treating COVID-19;Wanchao Yin et al.;《bioRxiv》;20201102;第1-49页 * |
| Synthesis and biological evaluation of pyrrolo[2,1-f][1,2,4]triazine C-nucleosides with a ribose, 2"-deoxyribose, and 2",3"- dideoxyribose sugar moiety;Qingfeng Li et al.;《ChemMedChem》;20171121;第13卷(第1期);第97-104页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112939981A (en) | 2021-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112939981B (en) | Nucleoside compound, pharmaceutically acceptable salt, composition and application thereof | |
| KR102630013B1 (en) | Pyrrolopyrimidine nucleosides and analogues thereof useful as antiviral agents | |
| CN114621229B (en) | Compounds or compositions for treating or preventing infectious peritonitis in cats | |
| WO2022017533A1 (en) | Compound useful as cdk7 kinase inhibitor and use thereof | |
| KR100331714B1 (en) | Treatment of Virus Infection Using Dideoxynucleotide Analogs | |
| CN112062800B (en) | Phosphoramidate derivatives of nucleoside compounds and uses thereof | |
| AU2023249953A1 (en) | Uracil derivative having viral growth inhibitory activity and pharmaceutical composition containing same | |
| CN114957383B (en) | Peptidomimetic compound, preparation method, pharmaceutical composition and use thereof | |
| KR20220141842A (en) | 5-(4-aminopyrrolo[2,1-F][1,2,4]triazin-7-yl)-2-cyano-3,4-dihydroxytetrahydrofuran derivative as antiviral agent | |
| JP2024178473A (en) | Bicyclic nitrogen-containing heterocyclic derivatives having virus proliferation inhibitory activity and pharmaceutical compositions containing the same | |
| US20240368174A1 (en) | Antiviral Heterocyclic Compounds | |
| CN113354684A (en) | Novel compound and application thereof | |
| EP0576227A2 (en) | 2'-Deoxy-2',2'-difluoro(2,6,8-substituted) purine nucleosides having anti-viral and anti-cancer activity and intermediates | |
| KR102367101B1 (en) | New compounds having cardiac protection effect and a medium composition for culturing stem cell using thereof | |
| IE913879A1 (en) | Use of xanthines for the preparation of a medicament¹effective for inhibiting the replication of human¹retroviruses | |
| CN117362344A (en) | Phosphate compound, preparation method and application thereof | |
| CN118126086A (en) | Phosphate compound, preparation method and application thereof | |
| CN113735927B (en) | Nucleotide analogue and preparation method and application thereof | |
| CN111995649A (en) | Pteridinone nucleotide analogue and pharmaceutical composition, preparation method and medical application thereof | |
| CN108299316B (en) | A kind of anti-influenza virus compound and its preparation method and application | |
| CN115141206B (en) | Alpha-lipoic acid lycorine conjugate and preparation method and application thereof | |
| CN118806753B (en) | Application of isoindolinone compounds in the preparation of antiviral drugs | |
| CN116687932B (en) | Medical uses of ((3-carbamoyl-5-fluoropyrazin-2-yl)oxy)methylisobutyrate | |
| US11957667B2 (en) | Inhibitors of positive strand RNA viruses | |
| US11542288B2 (en) | Antiviral compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |